ArticleInternational journal of nanomedicine2016
Hyaluronic acid reagent functional chitosan-PEI conjugate with AQP2-siRNA suppressed endometriotic lesion formation.
Article in International journal of nanomedicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 67 citations in OpenAlex.
- Tissue-specific gene delivery approaches.Bioengineering & translational medicine · 2026Review
- Three-dimensional patient-derived endometriosis model for drug evaluation.Acta obstetricia et gynecologica Scandinavica · 2026Article
- Nanotechnology for reproductive healthcare: a comprehensive review.Journal of nanobiotechnology · 2026Review
- The role of the y(+)L-type amino acid transporter 2 in promoting zinc absorption as zinc proteinate with moderate chelation strength in broiler primary duodenal epithelial cells.Journal of animal science · 2026Article
- Anti-Angiogenic RNAi-Based Treatment of Endometriosis in a Rat Model Using CXCR4-Targeted Peptide Nanoparticles.International journal of molecular sciences · 2025Article
- Article
- Targeted nanoparticles for imaging and therapy of endometriosis†.Biology of reproduction · 2024Review
- Emerging Trends in Nanotechnology for Endometriosis: Diagnosis to Therapy.Nanomaterials (Basel, Switzerland) · 2024Review
- Rethinking the application of nanoparticles in women's reproductive health and assisted reproduction.Nanomedicine (London, England) · 2024Review
- The emerging potential of siRNA nanotherapeutics in treatment of arthritis.Asian journal of pharmaceutical sciences · 2023Review
- iRGD-Targeted Peptide Nanoparticles for Anti-Angiogenic RNAi-Based Therapy of Endometriosis.Pharmaceutics · 2023Article
- Effects of Progestin on Modulation of the Expression of Biomarkers in Endometriosis.Biomedicines · 2023Article
- Highly specific neutrophil-mediated delivery of albumin nanoparticles to ectopic lesion for endometriosis therapy.Journal of nanobiotechnology · 2023Article
- Applications of nanomaterials in endometriosis treatment.Frontiers in bioengineering and biotechnology · 2023Review
- Nanotechnologies for the detection and treatment of endometriosis.Frontiers in biomaterials science · 2023Article
- Biomaterializing the advances in uterine tissue engineering.iScience · 2022Review
- Targeted Nanoparticles with High Heating Efficiency for the Treatment of Endometriosis with Systemically Delivered Magnetic Hyperthermia.Small (Weinheim an der Bergstrasse, Germany) · 2022Article
- Hyaluronic Acid-Modified Nanoplatforms as a Vector for Targeted Delivery of Autophagy-Related Gene to the Endometriotic Lesions in Mice.Frontiers in bioengineering and biotechnology · 2022Article
- Homing Peptide-Based Targeting of Tenascin-C and Fibronectin in Endometriosis.Nanomaterials (Basel, Switzerland) · 2021Article
- Nanomedicines for Endometriosis: Lessons Learned from Cancer Research.Small (Weinheim an der Bergstrasse, Germany) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To identify a new drug candidate for treating endometriosis which has fewer side effects, a new polymeric nanoparticle gene delivery system consisting of polyethylenimine-grafted chitosan oligosaccharide (CSO-PEI) with hyaluronic acid (HA) and small interfering RNA (siRNA) was designed. There was no obvious difference in sizes observed between (CSO-PEI/siRNA)HA and CSO-PEI/siRNA, but the fluorescence accumulation in the endometriotic lesion was more significant for (CSO-PEI/siRNA)HA compared with CSO-PEI/siRNA due to the specific binding of HA to CD44. In addition, the (CSO-PEI/siRNA)HA nanoparticle gene therapy significantly decreased the endometriotic lesion sizes with atrophy and degeneration of the ectopic endometrium. The epithelial cells of ectopic endometrium from rat models of endometriosis showed a significantly lower CD44 expression than control after treatment with (CSO-PEI/siRNA)HA. Furthermore, observation under an electron microscope showed no obvious toxic effect on the reproductive organs. Therefore, (CSO-PEI/siRNA)HA gene delivery system can be used as an effective method for the treatment of endometriosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.